Details of Disease

General Information of Disease (ID: DISDOA71)

• Disease Name: Vomiting
• Disease Class: MD90: Nausea/vomiting
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISDOA71: Vomiting
• ICD Code:
  ICD-11: ICD-11: MD90
  ICD-10: ICD-10: R11
  ICD-9: ICD-9: 787
  Expand ICD-11: 'MD90
  Expand ICD-10: 'R11
  Expand ICD-9: 787
• Disease Identifiers:
  MESH ID: D014839
  MedGen ID: 12124
  HPO ID: HP:0002013
  SNOMED CT ID: 249497008

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 14 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Alizapride	DM7BA57	Approved	Small molecular drug	[1]
Aprepitant	DM053KT	Approved	Small molecular drug	[2]
Dexamethasone	DMMWZET	Approved	Small molecular drug	[3]
Dimenhydrinate	DM264B3	Approved	Small molecular drug	[4]
Diphenhydramine	DMKQTBA	Approved	Small molecular drug	[5]
Fructose	DM43AN2	Approved	Small molecular drug	[1]
Haloperidol	DM96SE0	Approved	Small molecular drug	[6]
Lorazepam	DM84ZXF	Approved	Small molecular drug	[7]
Ondansetron	DMOTQ1I	Approved	Small molecular drug	[8]
Palonosetron	DMBHMOX	Approved	Small molecular drug	[9]
Promazine	DMZAL7W	Approved	Small molecular drug	[10]
Promethazine	DM6I5GR	Approved	Small molecular drug	[11]
Triflupromazine	DMKFQJP	Approved	Small molecular drug	[12]
Trimethobenzamide	DMPP4DT	Approved	Small molecular drug	[13]

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Lerisetron	DMOTCIU	Phase 3	Small molecular drug	[14]
APD-403	DM1VITS	Phase 2	NA	[15]
VOFOPITANT HYDROCHLORIDE	DMQMYP5	Phase 2	Small molecular drug	[16]

This Disease is Treated as An Indication in 14 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
MGX-006	DM6USPS	Discontinued in Preregistration	NA	[17]
APD-405	DMSBERP	Discontinued in Phase 2	NA	[18]
Ezlopitant	DMTUPZ2	Discontinued in Phase 2	Small molecular drug	[19]
Lurosetron	DMYR2U3	Discontinued in Phase 2	Small molecular drug	[20]
R-1068	DML7M3S	Discontinued in Phase 1	NA	[21]
AS-8112	DMIFDPL	Terminated	NA	[23]
CDP-492	DM4TYBR	Terminated	NA	[24]
DAU-6285	DMP9GFZ	Terminated	Small molecular drug	[25]
GK-128	DM4RKDU	Terminated	NA	[26]
GR-65630	DMRPE3D	Terminated	Small molecular drug	[27]
GR-82334	DMR2TZK	Terminated	NA	[28]
L-741671	DMRVXEQ	Terminated	Small molecular drug	[29]
SC-52150	DMKWJ59	Terminated	NA	[30]
SRSS-021	DM8MZWR	Terminated	NA	[31]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DLX-0201	DM0H6I8	Preclinical	NA	[22]

This Disease is Treated as An Indication in 5 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AS-9705	DMR01O4	Investigative	Small molecular drug	[14]
CL-508	DMU58CL	Investigative	Small molecular drug	[32]
CP-100263	DMLFNTH	Investigative	Small molecular drug	[14]
DBP-118	DMOFETJ	Investigative	NA	[32]
SUVN-504	DMZCKDH	Investigative	NA	[33]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Aprepitant FDA Label
• [3] Dexamethasone FDA Label
• [4] Dimenhydrinate FDA Label
• [5] Diphenhydramine FDA Label
• [6] Haloperidol FDA Label
• [7] Lorazepam FDA Label
• [8] Ondansetron FDA Label
• [9] Palonosetron FDA Label
• [10] Promazine FDA Label
• [11] Promethazine FDA Label
• [12] Triflupromazine FDA Label
• [13] Trimethobenzamide FDA Label
• [14] Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
• [15] ClinicalTrials.gov (NCT01857232) Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy. U.S. National Institutes of Health.
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5752).
• [17] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026430)
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031134)
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5751).
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002948)
• [21] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018362)
• [22] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019519)
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009088)
• [24] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016120)
• [25] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 246).
• [26] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002051)
• [27] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003534)
• [28] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005872)
• [29] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009849)
• [30] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001830)
• [31] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019090)
• [32] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [33] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 11).